In the BioHarmony Drug Report Database

"Preview" Icon

Aripiprazole lauroxil

Aristada, Abilify (aripiprazole lauroxil) is a small molecule pharmaceutical. Aripiprazole lauroxil was first approved as Aristada on 2004-06-04. It is used to treat schizophrenia and schizophrenia spectrum and other psychotic disorders in the USA. It has been approved in Europe to treat bipolar disorder and schizophrenia. The pharmaceutical is active against D(2) dopamine receptor. In addition, it is known to target 5-hydroxytryptamine receptor 1A, 5-hydroxytryptamine receptor 2C, 5-hydroxytryptamine receptor 6, D(4) dopamine receptor, 5-hydroxytryptamine receptor 7, histamine H1 receptor, 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 1B, and 5-hydroxytryptamine receptor 1D. Aristada’s patents are valid until 2035-09-08 (FDA).

 

Trade Name

 

Abilify, Abilify Maintena
 

Common Name

 

aripiprazole lauroxil
 

ChEMBL ID

 

CHEMBL2219425
 

Indication

 

bipolar disorder, schizophrenia, schizophrenia spectrum and other psychotic disorders
 

Drug Class

 

Antiulcer agents (benzimidazole derivatives)

Image (chem structure or protein)

Aripiprazole lauroxil structure rendering